Search results
Showing 1 to 7 of 7 results for alpelisib
Evidence-based recommendations on alpelisib (Piqray) with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults.
In development [GID-TA11263] Expected publication date: 05 February 2025
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]
Awaiting development [GID-TA11284] Expected publication date: TBC
Awaiting development [GID-TA11251] Expected publication date: TBC
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)
Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.
This guidance has been updated and replaced by NICE technology appraisal guidance 816.
NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018.